Bio-Techne Corporation develops, manufactures and sells
life science
Life is a quality that distinguishes matter that has biological processes, such as signaling and self-sustaining processes, from that which does not, and is defined by the capacity for growth, reaction to stimuli, metabolism, energy t ...
reagent
In chemistry, a reagent ( ) or analytical reagent is a substance or compound added to a system to cause a chemical reaction, or test if one occurs. The terms ''reactant'' and ''reagent'' are often used interchangeably, but reactant specifies a ...
s, instruments and services for the research,
diagnostic
Diagnosis is the identification of the nature and cause of a certain phenomenon. Diagnosis is used in many different disciplines, with variations in the use of logic, analytics, and experience, to determine " cause and effect". In systems engine ...
, and
bioprocessing
Bioprocess engineering, also biochemical engineering, is a specialization of chemical engineering or biological engineering. It deals with the design and development of equipment and processes for the manufacturing of products such as agriculture, ...
markets. The company's brands include R&D Systems, ProteinSimple, and Novus Biologicals.
[
]
History
The company was founded in 1976 by Dr. Roger C. Lucas as Research and Diagnostic Systems, Inc. In 1985, it merged into Techne Corporation and became a public company
A public company is a company whose ownership is organized via shares of stock which are intended to be freely traded on a stock exchange or in over-the-counter markets. A public (publicly traded) company can be listed on a stock exchange (l ...
.[
In March 2013, Charles (Chuck) Kummeth was named ]chief executive officer
A chief executive officer (CEO), also known as a central executive officer (CEO), chief administrator officer (CAO) or just chief executive (CE), is one of a number of corporate executives charged with the management of an organization especially ...
of the company.
In July 2013, the company acquired Bionostics for $104 million.
In February 2014, the company changed its name to Bio-Techne.
In April 2014, the company agreed to acquire Shanghai PrimeGene Bio-Tech Company (PrimeGene).
In July 2014, the company acquired Novus Biologicals for $60 million.
In August 2014, the company acquired ProteinSimple for $300 million.
In November 2014, the company agreed to acquire CyVek for $60 million plus up to an additional $135 million in earn-out payments.
In June 2015, the company agreed to acquire Cliniqa Corporation.
In March 2016, the company acquired Zephyrus Biosciences.
In July 2016, the company acquired Space Import-Export.
In August 2016, company acquired Advanced Cell Diagnostics for $250 million plus an additional $75 million in possible milestone payments.
In September 2017, the company acquired Trevigen.
In January 2018, the company acquired Atlanta Biologicals.
In June 2018, the company agreed to acquire Quad Technologies.
In August 2018, the company acquired Exosome Diagnostics for $250 million plus up to an additional $325 million in milestone payments.
In June 2019, the company acquired B-Mogen.
In April 2021, the company acquired Asuragen for $215 million plus up to an additional $105 million in milestone payments.
In June 2022, the business announced it would acquire Namocell Inc.
References
External links
*
* {{Finance links
, name = Bio-Techne Corporation
, google = TECH
, yahoo = TECH
, bloomberg = TECH:US
, reuters = TECH
, sec_cik = 842023
, nasdaq = TECH
1976 establishments in Minnesota
Biotechnology companies of the United States
Companies listed on the Nasdaq
Technology companies established in 1976